Notable Labs filed for voluntary Chapter 7 bankruptcy protection in October 2024, dissolving its board of directors and terminating key corporate executives as its business transitions to liquidation under a bankruptcy trustee.
Founded in 2014 out of Y Combinator's W15 batch by Pete Quinzio and Matthew De Silva, the Foster City, California precision medicine company developed a translational drug discovery platform for blood cancer. The company built an automated lab using robotics, custom software, and machine learning to test combinations of FDA-approved drugs on patient tissue samples. In a video pitch on Startup Pitches, De Silva shared that the company focused on taking tumors into the lab to screen off-patent drug combinations for oncologists, avoiding direct FDA clinical trial risk. In another video hosted by Labcyte Inc., De Silva described using acoustic liquid handling to perform high-throughput screening on low-cell-count leukemia samples, delivering custom drug response scores back to treating physicians.
As reported by Investing.com, Notable Labs filed its petition under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware on October 13, 2024. The filing prompted the immediate resignation of the entire board of directors, including Tuomo Pätsi, Thomas I. H. Dubin, Peter Feinberg, Michele Galen, Thomas Graney, and Michael Rice. Prior to the filing, on October 8, 2024, Chief Financial Officer Scott A. McPherson and Chief Scientific Officer Joseph Wagner were terminated, while Interim Chief Executive Officer and Chief Restructuring Officer Kaile A. Zagger moved to an advisory role. A Chapter 7 trustee was appointed to manage the liquidation of the company's assets.
Despite the bankruptcy liquidation, technical positions remain posted for the Foster City facility. For software engineers, Notable Labs lists a Senior Software Engineer - Full Stack role to build out the platform powering its robotic lab by creating backend APIs, web applications, and data tools using Python, React, and AWS.
On the R&D side, open scientific roles center on translating the company's ex vivo drug sensitivity testing platform into clinical CLIA tests for hematologic malignancies. The company has posted for a Product Development Scientist / Senior Assay Development Scientist to execute assay development and validation projects, as well as a Principal Product Development Scientist to design and lead these projects through a combination of planning and direct laboratory work.
| Role | Location | Work Mode | Salary |
|---|---|---|---|
| Product Development Scientist / Senior Assay Development Scientist | Foster City, CA | Onsite | Not listed |
| Senior Software Engineer - Full Stack | Foster city, CA | Onsite | Not listed |
| Principal Product Development Scientist | Foster City, CA | Onsite | Not listed |





